Aura Biosciences Statistics
Share Statistics
Aura Biosciences has 62M
shares outstanding. The number of shares has increased by 1.38%
in one year.
| Shares Outstanding | 62M |
| Shares Change (YoY) | 1.38% |
| Shares Change (QoQ) | 0.55% |
| Owned by Institutions (%) | 79.43% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,768 |
| FTD / Avg. Volume | 2.67% |
Short Selling Information
The latest short interest is 2.16M, so 4.31% of the outstanding
shares have been sold short.
| Short Interest | 2.16M |
| Short % of Shares Out | 4.31% |
| Short % of Float | 5.08% |
| Short Ratio (days to cover) | 13.63 |
Valuation Ratios
The PE ratio is -4.7 and the forward
PE ratio is -3.07.
Aura Biosciences's PEG ratio is
0.5.
| PE Ratio | -4.7 |
| Forward PE | -3.07 |
| PS Ratio | 0 |
| Forward PS | 2.1 |
| PB Ratio | 2.69 |
| P/FCF Ratio | -5.03 |
| PEG Ratio | 0.5 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aura Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.77,
with a Debt / Equity ratio of 0.12.
| Current Ratio | 10.77 |
| Quick Ratio | 10.77 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | -0.23 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-819,990.57 |
| Employee Count | 106 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 112K |
| Effective Tax Rate | -0.13% |
Stock Price Statistics
The stock price has increased by -15.79% in the
last 52 weeks. The beta is 0.43, so Aura Biosciences's
price volatility has been higher than the market average.
| Beta | 0.43 |
| 52-Week Price Change | -15.79% |
| 50-Day Moving Average | 5.89 |
| 200-Day Moving Average | 7.95 |
| Relative Strength Index (RSI) | 52.9 |
| Average Volume (20 Days) | 291,219 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -96.12M |
| Net Income | -86.92M |
| EBITDA | -85.58M |
| EBIT | -86.81M |
| Earnings Per Share (EPS) | -1.75 |
Full Income StatementBalance Sheet
The company has 31.69M in cash and 18.77M in
debt, giving a net cash position of 12.92M.
| Cash & Cash Equivalents | 31.69M |
| Total Debt | 18.77M |
| Net Cash | 12.92M |
| Retained Earnings | -374.23M |
| Total Assets | 155.4M |
| Working Capital | 122.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -79.81M
and capital expenditures -1.25M, giving a free cash flow of -81.06M.
| Operating Cash Flow | -79.81M |
| Capital Expenditures | -1.25M |
| Free Cash Flow | -81.06M |
| FCF Per Share | -1.63 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
